Detalhe da pesquisa
1.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res
; 25(1): 2, 2023 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631725
2.
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol
; 21(10): 1283-1295, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33002436
3.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Cancer
; 125(22): 3974-3984, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318460
4.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 620, 2019 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31234810
5.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 517, 2019 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146717
6.
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Gastric Cancer
; 22(4): 803-816, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30706247
7.
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Int J Cancer
; 139(10): 2336-42, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27428671
8.
Genetic markers of bevacizumab-induced hypertension.
Angiogenesis
; 17(3): 685-94, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24558090
9.
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
Angiogenesis
; 17(4): 909-20, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25012543
10.
Promotion of sleep by targeting the orexin system in rats, dogs and humans.
Nat Med
; 13(2): 150-5, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17259994
11.
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.
Nat Commun
; 15(1): 2153, 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461323
12.
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lancet Oncol
; 13(7): 724-33, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22608783
13.
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Clin Cancer Res
; 29(8): 1569-1581, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36730339
14.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809046
15.
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
Cancers (Basel)
; 14(11)2022 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681574
16.
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
NPJ Breast Cancer
; 8(1): 106, 2022 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117201
17.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638369
18.
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Clin Cancer Res
; 25(1): 64-72, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30206164
19.
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 22(15): 3755-63, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26920887
20.
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.
Cardiovasc Res
; 53(2): 341-7, 2002 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11827684